Clinical Chemistry · 2010 · 381 citations · 18 references
Life SciencesBiochemistryClinical BiochemistryGood Laboratory PracticeMolecular DiagnosticsBioanalytical Method ValidationLipoprotein AnalysisApolipoprotein B-containing LipoproteinsCholesterol Analysis In Body FluidsHigh-density Lipoprotein Cholesterol MeasurementLipid Profile AnalysisLow-density Lipoprotein Cholesterol MeasurementPlasma Cholesterol LevelsReference Measurement ProceduresVery Low-density Lipoprotein Analysis
BACKGROUND: Methods from 7 manufacturers and 1 distributor for directly measuring HDL cholesterol (C) and LDL-C were evaluated for imprecision, trueness, total error, and specificity in nonfrozen serum samples. METHODS: We performed each direct method according to the manufacturer's instructions, using a Roche/Hitachi 917 analyzer, and compared the results with those obtained with reference measurement procedures for HDL-C and LDL-C. Imprecision was estimated for 35 runs performed with frozen pooled serum specimens and triplicate measurements on each individual sample. Sera from 37 individuals without disease and 138 with disease (primarily dyslipidemic and cardiovascular) were measured by each method. Trueness and total error were evaluated from the difference between the direct methods and reference measurement procedures. Specificity was evaluated from the dispersion in differences observed. RESULTS: Imprecision data based on 4 frozen serum pools showed total CVs <3.7% for HDL-C and <4.4% for LDL-C. Bias for the nondiseased group ranged from -5.4% to 4.8% for HDL-C and from -6.8% to 1.1% for LDL-C, and for the diseased group from -8.6% to 8.8% for HDL-C and from -11.8% to 4.1% for LDL-C. Total error for the nondiseased group ranged from -13.4% to 13.6% for HDL-C and from -13.3% to 13.5% for LDL-C, and for the diseased group from -19.8% to 36.3% for HDL-C and from -26.6% to 31.9% for LDL-C. CONCLUSIONS: Six of 8 HDL-C and 5 of 8 LDL-C direct methods met the National Cholesterol Education Program total error goals for nondiseased individuals. All the methods failed to meet these goals for diseased individuals, however, because of lack of specificity toward abnormal lipoproteins.
18
Scott M. Grundy · JAMA · 1993 · 27.9K citations
Evaluation Expert Panel on Detection · JAMA · 2001 · 26K citations
Medicine, Cardiology, Otolaryngology +10
Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis
Steven E. Nissen, Stephen J. Nicholls, İlke Sipahi et al. · JAMA · 2006 · 2K citations
Archives of Internal Medicine · 1991 · 1.1K citations
Medicine, Cardiology, Dermatology +13